News from all angles
(MedPage Today) -- Phase II findings presented at the European Academy of Dermatology and Venereology meeting in Vienna showed promising early efficacy with abdakibart, an investigational interleukin…
Redirecting to MedPage Today in 3 seconds...
Share this story with your network